login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
IMMATICS NV (IMTX) Stock News
USA
- NASDAQ:IMTX -
NL0015285941
-
Common Stock
10.19
USD
-0.23 (-2.21%)
Last: 10/31/2025, 8:00:02 PM
10.19
USD
0 (0%)
After Hours:
10/31/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IMTX Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: https://immatics.com/
Immatics Appoints Amie Krause as Chief People Officer
7 days ago - By: https://immatics.com/
Immatics Appoints Amie Krause as Chief People Officer
14 days ago - By: https://immatics.com/
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
14 days ago - By: https://immatics.com/
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
23 days ago - By: Benzinga
- Mentions:
IVA
YCBD
IMAB
NBTX
...
12 Health Care Stocks Moving In Friday's After-Market Session
a month ago - By: https://immatics.com/
Immatics Appoints Venkat Ramanan as Chief Financial Officer
3 months ago - By: Zacks Investment Research
- Mentions:
ERJ
BFIN
New Strong Sell Stocks for August 15th
a month ago - By: Benzinga
- Mentions:
BOLT
GOVX
SCYX
LPTX
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
a month ago - By: https://immatics.com/
Immatics Appoints Venkat Ramanan as Chief Financial Officer
3 months ago - By: Zacks Investment Research
- Mentions:
DARE
Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates
3 months ago - By: https://immatics.com/
Immatics Announces Second Quarter 2025 Financial Results and Business Update
3 months ago - By: https://immatics.com/
Immatics Announces Second Quarter 2025 Financial Results and Business Update
3 months ago - By: Zacks Investment Research
- Mentions:
ARCT
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
DVAX
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
4 months ago - By: Yahoo Finance
- Mentions:
DB
Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)
5 months ago - By: https://immatics.com/
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
5 months ago - By: https://immatics.com/
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
6 months ago - By: https://immatics.com/
Immatics Announces First Quarter 2025 Financial Results and Business Update
6 months ago - By: https://immatics.com/
Immatics Announces First Quarter 2025 Financial Results and Business Update
6 months ago - By: Zacks Investment Research
- Mentions:
IBRX
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: Zacks Investment Research
- Mentions:
CRDF
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates
6 months ago - By: Zacks Investment Research
- Mentions:
DAWN
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: https://immatics.com/
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
6 months ago - By: https://immatics.com/
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
7 months ago - By: Yahoo Finance
- Mentions:
PLTR
AAPL
USB
Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds?
7 months ago - By: https://immatics.com/
Immatics Announces Full Year 2024 Financial Results and Business Update
7 months ago - By: https://immatics.com/
Immatics Announces Full Year 2024 Financial Results and Business Update
a year ago - By: https://immatics.com/
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
a year ago - By: https://immatics.com/
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
a year ago - By: https://immatics.com/
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
a year ago - By: https://immatics.com/
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Please enable JavaScript to continue using this application.